Gyre Therapeutics Inc. (GYRE NASDAQ) stock market data APIs
$7.1645
0.14(2%)
as of November 7, 2025
Try our APIs with
free plan!
Gyre Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Prev. Close
7.1645
Open
7.3091
High
7.3166
Low
7.0691
52 wk Range
6.11-19
Market Cap
655 M
P/E Ratio
180.25
Shares Outstanding
90 827 K
Revenue
102 M
EPS
0.03
Beta
7.11
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gyre Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gyre Therapeutics Inc. data using free add-ons & libraries
Get Gyre Therapeutics Inc. Fundamental Data
Gyre Therapeutics Inc. Fundamental data includes:
- Net Revenue: 102 M
- EBITDA: 11 462 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: 0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gyre Therapeutics Inc. News
New
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million pre...
Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.45 per share a year ago. These figures are ...
New Strong Sell Stocks for Oct. 17th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Gyre Therapeutics, Inc. GYRE is a biotechnology company which is focused on organ fibrosis and inflammatory diseases. The Za...
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
